Biogen Inc.

NASDAQ Global Select
1
Very Bullish +80

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

Biogen Inc. (NASDAQ: BIIB) has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) for approximately $5.6 billion, consisting of an upfront payment of $41.00 per share in cash and additional contingent value rights (CVRs) tied to sales thresholds for Syfovre. The...

3
Bullish +75

Biogen Zooms on Deal with TJ Biopharma

Biogen Inc. (NASDAQ: BIIB) saw its stock price rise on Monday after the company and TJ Biopharma announced a definitive agreement for Biogen to acquire exclusive rights to felzartamab in the Greater China Region. With this new agreement, Biogen now holds worldwide exclusive rights to...

4
Very Bullish +80

Biogen to acquire Apellis in $5.6bn deal

Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in a transaction designed to expand its portfolio within the immunology and rare disease sectors. The deal brings two commercially available, differentiated medicines, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection), which are expected to contribute...

5
Bullish +72

Biogen Inc. $BIIB Shares Purchased by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise increased its stake in Biogen Inc. (NASDAQ:BIIB) by 129% in the first quarter, acquiring an additional 4,466 shares to hold a total of 7,928 shares valued at $1.453 million. This move joins several other institutional investors who adjusted their positions in the...

6
Bullish +75

Alteogen Enters into a License Agreement with Biogen for Development ...

Biogen Inc. has entered into an exclusive license agreement with Alteogen Inc., a South Korean biopharmaceutical company, to develop and commercialize subcutaneous (SC) formulations of two biologics that utilize Alteogen's ALT-B4 technology. The deal involves ALT-B4, a proprietary recombinant human hyaluronidase enzyme developed using Alteogen's...

7
Somewhat Bullish +50

Biogen, UCB lupus drug dapirolizumab pegol meets phase 3 goal

Biogen (BIIB) and UCB announced on Monday that their investigational lupus drug, dapirolizumab pegol, successfully met its primary endpoint in a phase 3 clinical trial for systemic lupus erythematosus (SLE). The data showed that 50% of patients treated with the drug achieved a BICLA response...

8
Somewhat Bearish -25

AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug

At the Alzheimer's Association International Conference (AAIC) 2026, Biogen presented mid-stage data from its Phase 2 trial of diranersen, an antisense oligonucleotide developed with Ionis. The study validated the anti-tau hypothesis by demonstrating a correlation between tau reduction and clinical benefit in patients with Alzheimer's...

10
Bullish +75

Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen

Biogen has secured FDA breakthrough therapy designation for salanersen, an investigational drug intended to treat spinal muscular atrophy (SMA). This designation is based on positive results from a Phase 1b study involving children who had previously received gene therapy and subsequently gained critical motor functions...

12
Slightly Bullish +15

Stocks making the biggest moves premarket: Biogen, Vertiv, GE HealthCare, Generac & more

Biogen (BIIB) shares rose 0.7% in premarket trading after the biotechnology company reported second-quarter results that beat Wall Street consensus estimates for both revenue and earnings. The positive market reaction was further amplified by the company's decision to raise its full-year adjusted earnings per share...

13
Bearish -65

Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS

Biogen Inc. (BIIB) is set to report second-quarter 2026 earnings on July 29, with Wall Street anticipating a sharp decline in results. Analyst consensus estimates EPS at $2.10 and revenue at $2.46 billion, though the EPS forecast shows significant dispersion ranging from a loss of...

14
Somewhat Bullish +35

BIIB Soars: New Chief Legal Officer Appointed!

Biogen Inc. (NASDAQ: BIIB) saw its stock rise following the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. A veteran executive with over two decades of experience at Pfizer and Vertex, Parini will oversee global legal and compliance functions under...

15
Bullish +75

Biogen Idec Inc. (BIIB): This Biotechnology Stock Is On The Roll

Biogen Idec Inc. (NASDAQ: BIIB) recently presented new clinical data at the ISTH Congress in Amsterdam supporting its hemophilia A candidate, ELOCTATE, and its hemophilia B candidate, ALPROLIX. Both products are being developed with Swedish Orphan Biovitrum AB using Biogen's proprietary Fc fusion technology designed...

16
Bullish +65

Biogen pays up to $1B to add RayThera immunology assets - Stock Titan

Biogen (Nasdaq: BIIB) has entered a definitive agreement to acquire private biotech firm RayThera Inc. for up to $1 billion in total potential value. The deal structure includes an upfront payment combined with clinical and regulatory milestone payments, contingent on the achievement of future development...

17
Somewhat Bullish +50

Biogen beats estimates as Alzheimer’s drug gains momentum

Biogen Inc. reported better-than-expected first-quarter sales and profits, indicating that progress on its Alzheimer's therapies and cost-reduction strategies are helping to counteract pressures within its multiple sclerosis (MS) franchise. Revenue increased 2 percent to $2.5 billion, while adjusted earnings climbed 18 percent to $3.57 per...

18
Somewhat Bullish +50

What Is Driving Biogen’s Recent Drop and What Comes Next - Trefis

Biogen's stock, trading under the ticker BIIB on NASDAQ, experienced significant volatility following a strong performance at the beginning of February 2026 where it reached highs near $202. By early April 2026, however, the shares had declined to approximately $172. While the company boasts a...

19
Somewhat Bullish +45

Biogen Stock Rating Upgraded Amid Positive Data From Alzheimer's ...

Biogen (BIIB) stock received analyst upgrades following positive secondary data from its investigational tau-targeting drug, diranersen (BIIB080). Truist Securities upgraded the rating to Buy with a price target of $235, while Guggenheim maintained a Buy rating with a $260 target. The optimism stems from a...

20
Bullish +55

Biogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Wall Street Zen

Biogen (NASDAQ:BIIB) received a rating downgrade to 'Hold' from Wall Street Zen, though the broader analyst consensus remains a 'Moderate Buy' with a target price of $223.36. While some firms like Guggenheim raised their price targets, others such as Royal Bank of Canada lowered theirs,...